Clinical Trial Operations (GCP) Flashcards

A Clinical Research Coordinator (CRC) receives a shipment of investigational product that must be stored between 2-8°C. The temperature monitoring device packed with the shipment indicates a temperature of 10°C for the last four hours of transit. What is the most appropriate immediate action for the CRC?

Answer: Quarantine the shipment, document the temperature excursion, and notify the sponsor for instructions.

The integrity of the investigational product is paramount. A temperature excursion may affect the product's stability, safety, and efficacy. The correct procedure is to secure the product to prevent its use (quarantine), document the event thoroughly, and immediately contact the sponsor for guidance. The sponsor must assess the excursion data and determine if the product is still viable or must be destroyed or returned.

According to ICH GCP E6 (R2), which document is specifically maintained at the trial site to record all individuals who have been delegated significant trial-related duties by the Principal Investigator (PI)?

Answer: Delegation of Authority (DoA) Log

The Delegation of Authority (DoA) Log, also known as the Site Signature and Responsibility Log, is the essential document that prospectively captures all study staff members, their assigned roles, start/end dates, and signatures. While the Form FDA 1572 lists the PI and sub-investigators, it does not detail the specific delegated tasks for the entire team, such as coordinators, pharmacists, or research nurses.

A monitor is conducting source data verification (SDV) and notes that a blood pressure reading of '130/85' recorded in the electronic Case Report Form (eCRF) does not match the value of '135/80' written in the participant's original, signed progress note. This discrepancy is a violation of which core ALCOA-C principle of good documentation practice?

Answer: Accurate

The principle of "Accurate" documentation requires that the data recorded is a correct reflection of the source information. In this case, the discrepancy between the eCRF and the source document (the progress note) means the transcribed data in the eCRF is not accurate. The other principles, while important, do not directly address the correctness of the transcribed data.

A study participant is scheduled for their Week 4 visit, which has a protocol-specified visit window of +/- 3 days. The participant calls with a personal emergency and is unable to come to the clinic until 7 days after the target date, which is outside the visit window. How should the CRC classify and handle this occurrence?

Answer: As a protocol deviation that must be documented and reported according to site and sponsor procedures.

A protocol deviation is any unplanned excursion from the procedures defined in the IRB-approved protocol. A visit occurring outside the specified window is a common example of a deviation. This event must be documented in the source records and reported to the sponsor and/or IRB according to the protocol and institutional policies. It is not an adverse event, and while it's a deviation, it doesn't typically warrant immediate withdrawal unless it is part of a pattern of non-adherence or significantly impacts safety or data integrity.

Which of the following is the primary purpose of a Site Initiation Visit (SIV) conducted by the sponsor or a Contract Research Organization (CRO)?

Answer: To provide comprehensive, protocol-specific training to the site staff and verify readiness before the first participant is enrolled.

The Site Initiation Visit (SIV) occurs after regulatory approvals are in place but before participant enrollment begins. Its main purpose is to ensure the entire site team is thoroughly trained on the protocol, investigational product handling, data collection, and all trial-related duties to ensure the study is conducted correctly from the very start. It also serves to verify that the site has all necessary supplies and documentation to begin the trial.

By signing the Form FDA 1572, a Principal Investigator (PI) makes a binding commitment to the FDA to perform which of the following actions?

Answer: Ensure the investigation is conducted according to the current protocol and to personally supervise or conduct the investigation.

The Form FDA 1572 is a legally binding agreement between the Principal Investigator and the FDA. By signing it, the PI commits to personally conduct or supervise the investigation, follow the current protocol, and ensure all regulatory requirements (including IRB review) are met to protect the rights, safety, and welfare of subjects. The form is a statement of commitment to regulatory and ethical conduct, not a guarantee of enrollment numbers or a publication plan.